Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MLYCD | O95822 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5532723 | 1.00 | CA2 (0.39) | CA2ESR1KCNH2ALDH1A1POLB | |
| SCHEMBL5532725 | 1.00 | CA2 (0.39) | CA2ESR1KCNH2ALDH1A1POLB | |
| SCHEMBL1681789 | 0.79 | CA2 (0.40) | CA2ESR1KCNH2ALDH1A1POLB | |
| SCHEMBL13196035 | 0.79 | CA2 (0.40) | CA2ESR1KCNH2ALDH1A1POLB | |
| SCHEMBL1412322 | 0.79 | CA2 (0.40) | CA2ESR1KCNH2ALDH1A1POLB | |
| SCHEMBL17282769 | 0.79 | CA2 (0.40) | CA2ESR1KCNH2ALDH1A1POLB | |
| SCHEMBL1412323 | 0.79 | CA2 (0.40) | CA2ESR1KCNH2ALDH1A1POLB | |
| SCHEMBL11649038 | 0.78 | CA2 (0.36) | CA2ESR1KCNH2ALDH1A1POLB | |
| SCHEMBL5126776 | 0.77 | CA2 (0.39) | CA2ESR1KCNH2ALDH1A1POLB | |
| SCHEMBL11646409 | 0.77 | CA2 (0.39) | CA2ESR1KCNH2ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120252770-A1 | Chemical Compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-04 | — | — | US | disclosed |
| CN-101611015-B | Indazolyl ester and indazolyl amide derivatives for the treatment of glucocorticoid receptor mediated disorders | ASTRAZENECA AB SE | 2012-09-26 | — | — | CN | disclosed |
| EP-2102169-B1 | INDAZOLYL AMIDE DERIVATIVES FOR THE TREATMENT OF GLUCOCORTICOID RECEPTOR MEDIATED DISORDERS | ASTRAZENECA AB (SE) | 2012-06-20 | — | — | EP | disclosed |
| US-8143290-B2 | Chemical compounds 572 | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-20110071194-A1 | Chemical Compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-03-24 | — | — | US | disclosed |
| US-20100197644-A1 | Chemical Compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-05 | — | — | US | disclosed |
| US-7728030-B2 | Chemical compounds 572 | ASTRAZENECA AB (SE) | 2010-06-01 | — | — | US | disclosed |
| CN-101611015-A | Indazolyl ester and indazolyl amide derivatives for the treatment of glucocorticoid receptor mediated disorders | ASTRAZENECA AB (SE) | 2009-12-23 | — | — | CN | disclosed |
| EP-2102169-A1 | INDAZOLYL ESTER AND AMIDE DERIVATIVES FOR THE TREATMENT OF GLUCOCORTICOID RECEPTOR MEDIATED DISORDERS | AstraZeneca AB (SE) | 2009-09-23 | — | — | EP | disclosed |
| US-20080214641-A1 | Chemical compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2008-09-04 | — | — | US | disclosed |
| WO-2008076048-A1 | INDAZOLYL ESTER AND AMIDE DERIVATIVES FOR THE TREATMENT OF GLUCOCORTICOID RECEPTOR MEDIATED DISORDERS | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| US-4091029-A | RESOLVING AGENT FOR RACEMIC MIXTURES | ELI LILLY AND COMPANY (US) | 1978-05-23 | — | — | US | disclosed |
| US-3972925-A | RESOLUTION AGENT | ELI LILLY AND COMPANY (US) | 1976-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214641-A1 | Chemical compounds 572 | ABCG2, ABCB1, CYP11B2 | CA2 714/4885ESR1 1911/4885KCNH2 2344/4885 |
| US-20100197644-A1 | Chemical Compounds 572 | ABCG2, ABCB1, CYP11B2 | CA2 714/4885ESR1 1911/4885KCNH2 2344/4885 |
| US-20120252770-A1 | Chemical Compounds 572 | ABCG2, ABCB1, CYP11B2 | CA2 714/4885ESR1 1911/4885KCNH2 2344/4885 |
| US-20110071194-A1 | Chemical Compounds 572 | ABCG2, ABCB1, CYP11B2 | CA2 714/4885ESR1 1911/4885KCNH2 2344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.